Eurofins Scientific SEERFSF +0.58%80 ROC (Joel Greenblatt) % is 30.50% as of Dec. 2025, which is 29% below its 10-year median of 42.92. GuruFocus rates ERFSF with a GF Score™ of 80/100 and a GF Value™ of $77.44 (Fairly Valued). The stock has 7 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 80.57% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Eurofins Scientific SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 30.50%.
The historical rank and industry rank for Eurofins Scientific SE's ROC (Joel Greenblatt) % or its related term are showing as below:
ERFSF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.76 Med: 42.92 Max: 67.65
Current: 31.36
During the past 13 years, Eurofins Scientific SE's highest ROC (Joel Greenblatt) % was 67.65%. The lowest was 24.76%. And the median was 42.92%.
ERFSF's ROC (Joel Greenblatt) % is ranked better than 80.57% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs ERFSF: 31.36
Eurofins Scientific SE's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -14.90% per year.
Eurofins Scientific SE (OTCPK:ERFSF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Eurofins Scientific SE ROC (Joel Greenblatt) % Related Terms
Eurofins Scientific SE ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE ROC (Joel Greenblatt) % Chart
ERFSF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's ROC (Joel Greenblatt) % falls into.
Eurofins Scientific SE ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 30.50% mean?
Eurofins Scientific SE (ERFSF) has a ROC (Joel Greenblatt) % of 30.50% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eurofins Scientific SE and its competitors. This is 29% below median its historical median of 42.92. Over the past decade, Eurofins Scientific SE's ROC (Joel Greenblatt) % has ranged from 24.76 to 67.65. According to the industry distribution chart, Eurofins Scientific SE ranks #41 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 19.4%.
Is Eurofins Scientific SE's ROC (Joel Greenblatt) % too high?
Eurofins Scientific SE's current ROC (Joel Greenblatt) % of 30.50% is 29% below median its 10-year median of 42.92. Over the past 10 years, this metric has ranged from a low of 24.76 to a high of 67.65. Based on the distribution chart, Eurofins Scientific SE ranks #41 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #41 out of 211 companies for ROC (Joel Greenblatt) %. This places Eurofins Scientific SE in the top 19% of its industry — outperforming the majority of peers. Historically, Eurofins Scientific SE's own ROC (Joel Greenblatt) % has ranged from 24.76 to 67.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current ROC (Joel Greenblatt) % is 30.50%, which is 29% below median its own 10-year median of 42.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $77.44, compared to a current price of $76.93 — trading 0.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 30.50%, which is 29% below median its 10-year median of 42.92. Eurofins Scientific SE's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current ROC (Joel Greenblatt) % is 30.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be undervalued.
The current stock price of $76.93 is trading 0.7% below its estimated GF Value™ of $77.44.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
ROC (Joel Greenblatt) %: 30.50% (29% below median its 10-year median of 42.92)
GF Value™: $77.44 vs. price of $76.93 (0.7% below fair value)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
80GF Score
Get the complete analysis for ERFSF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
